Global Nuclear Receptor ROR-Gamma Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Nuclear Receptor ROR-Gamma market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Nuclear Receptor ROR-Gamma include 4SC AG, Vitae Pharmaceuticals, Inc., Visionary Pharmaceuticals, Inc., Teijin Pharma Limited, Reata Pharmaceuticals, Inc., Phenex Pharmaceuticals AG, Nuevolution AB, Lead Pharma Holding B.V. and Karo Bio AB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Nuclear Receptor ROR-Gamma, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nuclear Receptor ROR-Gamma, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Receptor ROR-Gamma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Receptor ROR-Gamma revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nuclear Receptor ROR-Gamma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nuclear Receptor ROR-Gamma revenue, projected growth trends, production technology, application and end-user industry.
Nuclear Receptor ROR-Gamma Segment by Company
4SC AG
Vitae Pharmaceuticals, Inc.
Visionary Pharmaceuticals, Inc.
Teijin Pharma Limited
Reata Pharmaceuticals, Inc.
Phenex Pharmaceuticals AG
Nuevolution AB
Lead Pharma Holding B.V.
Karo Bio AB
Hanmi Pharmaceuticals, Co. Ltd.
GlaxoSmithKline Plc
Genfit SA
Genentech, Inc.
Celgene Corporation
Bristol-Myers Squibb Company
Brickell Biotech, Inc.
Biogen, Inc.
Aurigene Discovery Technologies Limited
Arrien Pharmaceuticals, LLC
Advinus Therapeutics Ltd.
Nuclear Receptor ROR-Gamma Segment by Type
BBI-6000
GSK-2981278
INV-17
VPR-66
Others
Nuclear Receptor ROR-Gamma Segment by Application
Hospital
Clinic
Others
Nuclear Receptor ROR-Gamma Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR-Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR-Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR-Gamma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Nuclear Receptor ROR-Gamma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Nuclear Receptor ROR-Gamma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Receptor ROR-Gamma revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Nuclear Receptor ROR-Gamma market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Nuclear Receptor ROR-Gamma is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Nuclear Receptor ROR-Gamma include 4SC AG, Vitae Pharmaceuticals, Inc., Visionary Pharmaceuticals, Inc., Teijin Pharma Limited, Reata Pharmaceuticals, Inc., Phenex Pharmaceuticals AG, Nuevolution AB, Lead Pharma Holding B.V. and Karo Bio AB, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Nuclear Receptor ROR-Gamma, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Nuclear Receptor ROR-Gamma, also provides the revenue of main regions and countries. Of the upcoming market potential for Nuclear Receptor ROR-Gamma, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nuclear Receptor ROR-Gamma revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Nuclear Receptor ROR-Gamma market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Nuclear Receptor ROR-Gamma revenue, projected growth trends, production technology, application and end-user industry.
Nuclear Receptor ROR-Gamma Segment by Company
4SC AG
Vitae Pharmaceuticals, Inc.
Visionary Pharmaceuticals, Inc.
Teijin Pharma Limited
Reata Pharmaceuticals, Inc.
Phenex Pharmaceuticals AG
Nuevolution AB
Lead Pharma Holding B.V.
Karo Bio AB
Hanmi Pharmaceuticals, Co. Ltd.
GlaxoSmithKline Plc
Genfit SA
Genentech, Inc.
Celgene Corporation
Bristol-Myers Squibb Company
Brickell Biotech, Inc.
Biogen, Inc.
Aurigene Discovery Technologies Limited
Arrien Pharmaceuticals, LLC
Advinus Therapeutics Ltd.
Nuclear Receptor ROR-Gamma Segment by Type
BBI-6000
GSK-2981278
INV-17
VPR-66
Others
Nuclear Receptor ROR-Gamma Segment by Application
Hospital
Clinic
Others
Nuclear Receptor ROR-Gamma Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Receptor ROR-Gamma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Receptor ROR-Gamma and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Receptor ROR-Gamma.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Nuclear Receptor ROR-Gamma in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Nuclear Receptor ROR-Gamma company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nuclear Receptor ROR-Gamma revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
205 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Nuclear Receptor ROR-Gamma Market by Type
- 1.2.1 Global Nuclear Receptor ROR-Gamma Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 BBI-6000
- 1.2.3 GSK-2981278
- 1.2.4 INV-17
- 1.2.5 VPR-66
- 1.2.6 Others
- 1.3 Nuclear Receptor ROR-Gamma Market by Application
- 1.3.1 Global Nuclear Receptor ROR-Gamma Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Nuclear Receptor ROR-Gamma Market Dynamics
- 2.1 Nuclear Receptor ROR-Gamma Industry Trends
- 2.2 Nuclear Receptor ROR-Gamma Industry Drivers
- 2.3 Nuclear Receptor ROR-Gamma Industry Opportunities and Challenges
- 2.4 Nuclear Receptor ROR-Gamma Industry Restraints
- 3 Global Growth Perspective
- 3.1 Global Nuclear Receptor ROR-Gamma Market Perspective (2020-2031)
- 3.2 Global Nuclear Receptor ROR-Gamma Growth Trends by Region
- 3.2.1 Global Nuclear Receptor ROR-Gamma Market Size by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Nuclear Receptor ROR-Gamma Market Size by Region (2020-2025)
- 3.2.3 Global Nuclear Receptor ROR-Gamma Market Size by Region (2026-2031)
- 4 Competitive Landscape by Players
- 4.1 Global Nuclear Receptor ROR-Gamma Revenue by Players
- 4.1.1 Global Nuclear Receptor ROR-Gamma Revenue by Players (2020-2025)
- 4.1.2 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Players (2020-2025)
- 4.1.3 Global Nuclear Receptor ROR-Gamma Players Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Nuclear Receptor ROR-Gamma Key Players Ranking, 2023 VS 2024 VS 2025
- 4.3 Global Nuclear Receptor ROR-Gamma Key Players Headquarters & Area Served
- 4.4 Global Nuclear Receptor ROR-Gamma Players, Product Type & Application
- 4.5 Global Nuclear Receptor ROR-Gamma Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Nuclear Receptor ROR-Gamma Market CR5 and HHI
- 4.6.3 2024 Nuclear Receptor ROR-Gamma Tier 1, Tier 2, and Tier 3
- 5 Nuclear Receptor ROR-Gamma Market Size by Type
- 5.1 Global Nuclear Receptor ROR-Gamma Revenue by Type (2020 VS 2024 VS 2031)
- 5.2 Global Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 5.3 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Type (2020-2031)
- 6 Nuclear Receptor ROR-Gamma Market Size by Application
- 6.1 Global Nuclear Receptor ROR-Gamma Revenue by Application (2020 VS 2024 VS 2031)
- 6.2 Global Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 6.3 Global Nuclear Receptor ROR-Gamma Revenue Market Share by Application (2020-2031)
- 7 Company Profiles
- 7.1 4SC AG
- 7.1.1 4SC AG Comapny Information
- 7.1.2 4SC AG Business Overview
- 7.1.3 4SC AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.1.4 4SC AG Nuclear Receptor ROR-Gamma Product Portfolio
- 7.1.5 4SC AG Recent Developments
- 7.2 Vitae Pharmaceuticals, Inc.
- 7.2.1 Vitae Pharmaceuticals, Inc. Comapny Information
- 7.2.2 Vitae Pharmaceuticals, Inc. Business Overview
- 7.2.3 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.2.4 Vitae Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.2.5 Vitae Pharmaceuticals, Inc. Recent Developments
- 7.3 Visionary Pharmaceuticals, Inc.
- 7.3.1 Visionary Pharmaceuticals, Inc. Comapny Information
- 7.3.2 Visionary Pharmaceuticals, Inc. Business Overview
- 7.3.3 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.3.4 Visionary Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.3.5 Visionary Pharmaceuticals, Inc. Recent Developments
- 7.4 Teijin Pharma Limited
- 7.4.1 Teijin Pharma Limited Comapny Information
- 7.4.2 Teijin Pharma Limited Business Overview
- 7.4.3 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.4.4 Teijin Pharma Limited Nuclear Receptor ROR-Gamma Product Portfolio
- 7.4.5 Teijin Pharma Limited Recent Developments
- 7.5 Reata Pharmaceuticals, Inc.
- 7.5.1 Reata Pharmaceuticals, Inc. Comapny Information
- 7.5.2 Reata Pharmaceuticals, Inc. Business Overview
- 7.5.3 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.5.4 Reata Pharmaceuticals, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.5.5 Reata Pharmaceuticals, Inc. Recent Developments
- 7.6 Phenex Pharmaceuticals AG
- 7.6.1 Phenex Pharmaceuticals AG Comapny Information
- 7.6.2 Phenex Pharmaceuticals AG Business Overview
- 7.6.3 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.6.4 Phenex Pharmaceuticals AG Nuclear Receptor ROR-Gamma Product Portfolio
- 7.6.5 Phenex Pharmaceuticals AG Recent Developments
- 7.7 Nuevolution AB
- 7.7.1 Nuevolution AB Comapny Information
- 7.7.2 Nuevolution AB Business Overview
- 7.7.3 Nuevolution AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.7.4 Nuevolution AB Nuclear Receptor ROR-Gamma Product Portfolio
- 7.7.5 Nuevolution AB Recent Developments
- 7.8 Lead Pharma Holding B.V.
- 7.8.1 Lead Pharma Holding B.V. Comapny Information
- 7.8.2 Lead Pharma Holding B.V. Business Overview
- 7.8.3 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.8.4 Lead Pharma Holding B.V. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.8.5 Lead Pharma Holding B.V. Recent Developments
- 7.9 Karo Bio AB
- 7.9.1 Karo Bio AB Comapny Information
- 7.9.2 Karo Bio AB Business Overview
- 7.9.3 Karo Bio AB Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.9.4 Karo Bio AB Nuclear Receptor ROR-Gamma Product Portfolio
- 7.9.5 Karo Bio AB Recent Developments
- 7.10 Hanmi Pharmaceuticals, Co. Ltd.
- 7.10.1 Hanmi Pharmaceuticals, Co. Ltd. Comapny Information
- 7.10.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
- 7.10.3 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.10.4 Hanmi Pharmaceuticals, Co. Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.10.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- 7.11 GlaxoSmithKline Plc
- 7.11.1 GlaxoSmithKline Plc Comapny Information
- 7.11.2 GlaxoSmithKline Plc Business Overview
- 7.11.3 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.11.4 GlaxoSmithKline Plc Nuclear Receptor ROR-Gamma Product Portfolio
- 7.11.5 GlaxoSmithKline Plc Recent Developments
- 7.12 Genfit SA
- 7.12.1 Genfit SA Comapny Information
- 7.12.2 Genfit SA Business Overview
- 7.12.3 Genfit SA Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.12.4 Genfit SA Nuclear Receptor ROR-Gamma Product Portfolio
- 7.12.5 Genfit SA Recent Developments
- 7.13 Genentech, Inc.
- 7.13.1 Genentech, Inc. Comapny Information
- 7.13.2 Genentech, Inc. Business Overview
- 7.13.3 Genentech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.13.4 Genentech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.13.5 Genentech, Inc. Recent Developments
- 7.14 Celgene Corporation
- 7.14.1 Celgene Corporation Comapny Information
- 7.14.2 Celgene Corporation Business Overview
- 7.14.3 Celgene Corporation Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.14.4 Celgene Corporation Nuclear Receptor ROR-Gamma Product Portfolio
- 7.14.5 Celgene Corporation Recent Developments
- 7.15 Bristol-Myers Squibb Company
- 7.15.1 Bristol-Myers Squibb Company Comapny Information
- 7.15.2 Bristol-Myers Squibb Company Business Overview
- 7.15.3 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.15.4 Bristol-Myers Squibb Company Nuclear Receptor ROR-Gamma Product Portfolio
- 7.15.5 Bristol-Myers Squibb Company Recent Developments
- 7.16 Brickell Biotech, Inc.
- 7.16.1 Brickell Biotech, Inc. Comapny Information
- 7.16.2 Brickell Biotech, Inc. Business Overview
- 7.16.3 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.16.4 Brickell Biotech, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.16.5 Brickell Biotech, Inc. Recent Developments
- 7.17 Biogen, Inc.
- 7.17.1 Biogen, Inc. Comapny Information
- 7.17.2 Biogen, Inc. Business Overview
- 7.17.3 Biogen, Inc. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.17.4 Biogen, Inc. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.17.5 Biogen, Inc. Recent Developments
- 7.18 Aurigene Discovery Technologies Limited
- 7.18.1 Aurigene Discovery Technologies Limited Comapny Information
- 7.18.2 Aurigene Discovery Technologies Limited Business Overview
- 7.18.3 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.18.4 Aurigene Discovery Technologies Limited Nuclear Receptor ROR-Gamma Product Portfolio
- 7.18.5 Aurigene Discovery Technologies Limited Recent Developments
- 7.19 Arrien Pharmaceuticals, LLC
- 7.19.1 Arrien Pharmaceuticals, LLC Comapny Information
- 7.19.2 Arrien Pharmaceuticals, LLC Business Overview
- 7.19.3 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.19.4 Arrien Pharmaceuticals, LLC Nuclear Receptor ROR-Gamma Product Portfolio
- 7.19.5 Arrien Pharmaceuticals, LLC Recent Developments
- 7.20 Advinus Therapeutics Ltd.
- 7.20.1 Advinus Therapeutics Ltd. Comapny Information
- 7.20.2 Advinus Therapeutics Ltd. Business Overview
- 7.20.3 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Revenue and Gross Margin (2020-2025)
- 7.20.4 Advinus Therapeutics Ltd. Nuclear Receptor ROR-Gamma Product Portfolio
- 7.20.5 Advinus Therapeutics Ltd. Recent Developments
- 8 North America
- 8.1 North America Nuclear Receptor ROR-Gamma Revenue (2020-2031)
- 8.2 North America Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 8.2.1 North America Nuclear Receptor ROR-Gamma Revenue by Type (2020-2025)
- 8.2.2 North America Nuclear Receptor ROR-Gamma Revenue by Type (2026-2031)
- 8.3 North America Nuclear Receptor ROR-Gamma Revenue Share by Type (2020-2031)
- 8.4 North America Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 8.4.1 North America Nuclear Receptor ROR-Gamma Revenue by Application (2020-2025)
- 8.4.2 North America Nuclear Receptor ROR-Gamma Revenue by Application (2026-2031)
- 8.5 North America Nuclear Receptor ROR-Gamma Revenue Share by Application (2020-2031)
- 8.6 North America Nuclear Receptor ROR-Gamma Revenue by Country
- 8.6.1 North America Nuclear Receptor ROR-Gamma Revenue by Country (2020 VS 2024 VS 2031)
- 8.6.2 North America Nuclear Receptor ROR-Gamma Revenue by Country (2020-2025)
- 8.6.3 North America Nuclear Receptor ROR-Gamma Revenue by Country (2026-2031)
- 8.6.4 United States
- 8.6.5 Canada
- 9 Europe
- 9.1 Europe Nuclear Receptor ROR-Gamma Revenue (2020-2031)
- 9.2 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 9.2.1 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2020-2025)
- 9.2.2 Europe Nuclear Receptor ROR-Gamma Revenue by Type (2026-2031)
- 9.3 Europe Nuclear Receptor ROR-Gamma Revenue Share by Type (2020-2031)
- 9.4 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 9.4.1 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2020-2025)
- 9.4.2 Europe Nuclear Receptor ROR-Gamma Revenue by Application (2026-2031)
- 9.5 Europe Nuclear Receptor ROR-Gamma Revenue Share by Application (2020-2031)
- 9.6 Europe Nuclear Receptor ROR-Gamma Revenue by Country
- 9.6.1 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2020 VS 2024 VS 2031)
- 9.6.2 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2020-2025)
- 9.6.3 Europe Nuclear Receptor ROR-Gamma Revenue by Country (2026-2031)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 10 China
- 10.1 China Nuclear Receptor ROR-Gamma Revenue (2020-2031)
- 10.2 China Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 10.2.1 China Nuclear Receptor ROR-Gamma Revenue by Type (2020-2025)
- 10.2.2 China Nuclear Receptor ROR-Gamma Revenue by Type (2026-2031)
- 10.3 China Nuclear Receptor ROR-Gamma Revenue Share by Type (2020-2031)
- 10.4 China Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 10.4.1 China Nuclear Receptor ROR-Gamma Revenue by Application (2020-2025)
- 10.4.2 China Nuclear Receptor ROR-Gamma Revenue by Application (2026-2031)
- 10.5 China Nuclear Receptor ROR-Gamma Revenue Share by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Nuclear Receptor ROR-Gamma Revenue (2020-2031)
- 11.2 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 11.2.1 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2020-2025)
- 11.2.2 Asia Nuclear Receptor ROR-Gamma Revenue by Type (2026-2031)
- 11.3 Asia Nuclear Receptor ROR-Gamma Revenue Share by Type (2020-2031)
- 11.4 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 11.4.1 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2020-2025)
- 11.4.2 Asia Nuclear Receptor ROR-Gamma Revenue by Application (2026-2031)
- 11.5 Asia Nuclear Receptor ROR-Gamma Revenue Share by Application (2020-2031)
- 11.6 Asia Nuclear Receptor ROR-Gamma Revenue by Country
- 11.6.1 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2020 VS 2024 VS 2031)
- 11.6.2 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2020-2025)
- 11.6.3 Asia Nuclear Receptor ROR-Gamma Revenue by Country (2026-2031)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Nuclear Receptor ROR-Gamma Revenue (2020-2031)
- 12.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2020-2031)
- 12.2.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2020-2025)
- 12.2.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Type (2026-2031)
- 12.3 SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Type (2020-2031)
- 12.4 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2020-2031)
- 12.4.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2020-2025)
- 12.4.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Application (2026-2031)
- 12.5 SAMEA Nuclear Receptor ROR-Gamma Revenue Share by Application (2020-2031)
- 12.6 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country
- 12.6.1 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2020 VS 2024 VS 2031)
- 12.6.2 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2020-2025)
- 12.6.3 SAMEA Nuclear Receptor ROR-Gamma Revenue by Country (2026-2031)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


